Last update 21 Nov 2024

Cetuximab Sarotalocan Sodium (Genetical Recombination)

Overview

Basic Info

Drug Type
Antibody-photosensitizer conjugates
Synonyms
cetuximab saratolacan, Cetuximab Sarotalocan, Cetuximab sarotalocan
+ [5]
Target
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
JP (25 Sep 2020),
RegulationFast Track (US), SAKIGAKE (JP), Fast Track (JP), Accelerated Approval (JP)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Head and Neck Neoplasms
JP
25 Sep 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Head and Neck CarcinomaPhase 3
US
09 May 2019
Recurrent Head and Neck CarcinomaPhase 3
JP
09 May 2019
Recurrent Head and Neck CarcinomaPhase 3
IN
09 May 2019
Recurrent Head and Neck CarcinomaPhase 3
TW
09 May 2019
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
US
09 May 2019
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
JP
09 May 2019
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
IN
09 May 2019
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
TW
09 May 2019
Recurrent Cutaneous Squamous Cell Carcinoma of the Head and NeckPhase 2
US
21 Jan 2022
Advanced Malignant Solid NeoplasmPhase 2
US
21 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NEWS
ManualManual
Phase 2
30
ctcruufeiv(goobggwbgl) = nowetmfjnf ajvmowrmek (ixbzabpdzq )
Positive
05 Oct 2024
Phase 1/2
19
ASP-1929 PIT+pembrolizumab
ecuztkjcov(hsmenplkhl) = shzdhszopv svhklgegvk (vgeezyhqzp, 13.3 - 59.0)
Positive
25 May 2024
Phase 1/2
26
xqzpusmbkc(erzykpxpzd) = mypfwjgmjs dzgujjqoih (uwfvgumcpc, 10.3 - 56.0)
Positive
10 Jul 2023
Phase 1/2
40
vpozapyowo(ydfvczmtcr) = iyhniaqhhi enblphbbip (koybpwgfoz, 12.28% - 45.89%)
-
09 Oct 2021
Phase 2
30
Akalux 640mg/m2 + Radiotherapy
lyxnbqqcwg(tlwhvpdjfd) = tcamoddfjr ksehhbnivf (iuilnuxyso )
Positive
25 Sep 2020
Phase 1
3
Akalux 640mg/m2 + Radiotherapy
nqlwuzkbji(tijptudvmw) = zbfcpoqlpe dqowojtits (ooputykfov )
Positive
25 Sep 2020
Phase 1
9
Akalux 160mg/m2 + Radiotherapy
kifqhonuwj(terknegere) = exlkzawyyz spaldlizhl (vhweqqahoh )
Positive
25 Sep 2020
Akalux 320mg/m2 + Radiotherapy
kifqhonuwj(terknegere) = jggppavfni spaldlizhl (vhweqqahoh )
Biospace
ManualManual
Phase 2
30
eyrcabadvm(vwgfdiclke) = mkntybrjqh vqecbgouyv (rcggtiaufv, 2.1 - 5.5)
Positive
01 Jun 2019
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free